Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.34 |
| ▸ | TPMT | P51580 | 1/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.34 |
| ▸ | TUBB | P07437 | 1/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.34 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.34 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.34 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.34 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.34 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.34 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.34 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.34 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.34 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.34 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodomethane SCHEMBL4667431 | 0.85 | HSD17B10 (0.38) | HSD17B10CA2CA4TUBB1TUBB4A | |
| SCHEMBL10986 | 0.84 | CA2 (0.41) | HSD17B10CA2CA4TUBB1TUBB4A | |
| SCHEMBL19607137 | 0.84 | HSD17B10 (0.45) | HSD17B10CA2CA4TUBB1TPMT | |
| SCHEMBL3521150 | 0.78 | HSD17B10 (0.50) | HSD17B10CA2CA4TUBB1TPMT | |
| SCHEMBL17875684 | 0.78 | HSD17B10 (0.50) | HSD17B10CA2CA4TUBB1TPMT | |
| SCHEMBL17210735 | 0.78 | TTR (0.39) | CA2CA4TUBB1TPMTPDGFRB | |
| SCHEMBL31500460 | 0.77 | ALOX15 (0.47) | CA2CA4TUBB1TUBB4ATUBB | |
| SCHEMBL19607300 | 0.77 | KDM4E (0.43) | HSD17B10CA2CA4TUBB1TPMT | |
| SCHEMBL930657 | 0.77 | KDM4E (0.40) | HSD17B10CA2CA4TUBB1MAPT | |
| SCHEMBL30017049 | 0.77 | KDM4E (0.43) | HSD17B10CA2CA4TUBB1TPMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116947903-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116261564-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | HSD17B10 1464/4885CA2 3164/4885CA4 2786/4885 |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | HSD17B10 1464/4885CA2 3164/4885CA4 2786/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | HSD17B10 1464/4885CA2 3164/4885CA4 2786/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | HSD17B10 2859/4885CA2 363/4885CA4 1016/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | HSD17B10 1492/4885CA2 392/4885CA4 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.